The popularity of copyright’s blockbuster initially drove a boom for major pharmaceutical companies, but recent developments present a uncertain outlook for investors. Generic alternatives are eating into earnings, https://jimisef454638.idblogmaker.com/39942615/the-blue-pill-and-the-pharmaceutical-industry-a-precarious-play